AM6527

AM6527 is an orally bioavailable small molecule inhibitor of fatty acid amide hydrolase (FAAH), developed by MAK Scientific. FAAH is the primary enzyme responsible for the metabolic degradation of the endocannabinoid anandamide (N-arachidonoylethanolamine). By blocking FAAH activity, AM6527 elevates endogenous levels of anandamide, which subsequently activates cannabinoid receptors to produce analgesic and anti-inflammatory effects. This mechanism is intended to provide therapeutic benefits for pain and inflammatory conditions while avoiding the central psychotropic side effects typically associated with direct CB1 receptor agonists. AM6527 is currently in the preclinical stage of development, with potential applications in treating inflammatory pain, neuropathic pain, and drug addiction.